Business
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nTravere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:\n\nGuggenheim's 2nd Annual Healthcare Innovation Conference\nPresenting on Tuesday, November 11, 2025, at 9:00 a.m. ET\n\nStifel 2025 Healthcare Conference\nWednesday, November 12, 2025\n\nTD Cowen Immunology & Inflammation Summit\nPresenting on Thursday, November 13, 2025, at 4:00 p.m. ET\n\nJefferies Global Healthcare Conference\nPresenting on Tuesday, November 18, 2025, at 3:00 p.m. GMT (10:00 a.m. ET)\n\n8th Annual Evercore Healthcare Conference\nPresenting on Tuesday, December 2, 2025, at 10:50 a.m. ET\n\nPiper Sandler 37th Annual Healthcare Conference\nWednesday, December 3, 2025\n\nLive webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.\n\nAbout Travere Therapeutics\n\nAt Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20251104923461/en/\n\nInvestors:\n888-969-7879\[email protected]\n\nMedia:\n888-969-7879\[email protected]\n\nSource: Travere Therapeutics, Inc.","length":3409,"tagName":"div"}]